
Home » AEROVANCE SECURES $60 MILLION IN FINANCING
AEROVANCE SECURES $60 MILLION IN FINANCING
Aerovance Inc., a biopharmaceutical company with a portfolio of clinical-stage drugs targeting severe respiratory and inflammatory diseases, today announced it has secured $60 million in Series C financing.
Drug Newswire (http://www.drugnewswire.com/1834/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
08Sep
-
15Sep
-
20Sep
-
21Sep
-
22Sep
-
11Oct